arrow_back Back to App

Strengthening Foreign Drug Facility Inspections for Citizen Safety.

New rules aim to enhance the safety of drugs available in the U.S. by allowing unannounced inspections of foreign manufacturing facilities. This means citizens can be more confident about the quality and safety of imported medications, as inspections will be more effective. Companies that do not agree to such inspections may face difficulties in bringing their products to the U.S. market.
Key points
Unannounced Inspections: U.S. authorities can conduct unannounced inspections of foreign drug manufacturing facilities supplying the U.S., enhancing product safety.
Exceptions to Notice: Advance notice for inspections will only be given if required by local law or to protect public health, always with minimal lead time.
Consequences of Refusal: Foreign companies refusing unannounced inspections may be deemed non-compliant, potentially blocking their drugs from the U.S. market.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_S_3509
Sponsor: Sen. Braun, Mike [R-IN]
Process start date: 2022-01-13
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Creating Efficiency in Foreign Facility Inspections Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_S_3509.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2022-01-13.

What are the main provisions?

Key points include:

  • Unannounced Inspections: U.S. authorities can conduct unannounced inspections of foreign drug manufacturing facilities supplying the U.S., enhancing product safety.
  • Exceptions to Notice: Advance notice for inspections will only be given if required by local law or to protect public health, always with minimal lead time.
  • Consequences of Refusal: Foreign companies refusing unannounced inspections may be deemed non-compliant, potentially blocking their drugs from the U.S. market.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Braun, Mike [R-IN].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

CATEGORIES

Health